当前位置: X-MOL 学术Bipolar Disord. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Lithium as a first-step option for acute phase pharmacotherapy of bipolar depression
Bipolar Disorders ( IF 5.4 ) Pub Date : 2021-07-06 , DOI: 10.1111/bdi.13113
Sune Puggaard Vogt Straszek 1, 2 , René E Nielsen 1, 2 , Zoltan Kovacs 1, 2 , Rasmus W Licht 1, 2
Affiliation  

A recently published summary of the 2020 clinical practice guidelines from the Royal Australian and New Zealand College of Psychiatrists provides recommendations on management of bipolar disorder (1). The acute phase pharmacotherapy of a depressive episode in patients with bipolar disorder, in the following referred to as treatment of bipolar depression, is especially challenging. The evidence for lithium as a treatment of bipolar depression is limited and conflicting (2), and therefore the positioning of this drug for the treatment of bipolar depression in upcoming guidelines is of particular interest.

中文翻译:

锂作为双相抑郁急性期药物治疗的第一步选择

澳大利亚和新西兰皇家精神病学家学院最近发布的 2020 年临床实践指南摘要提供了双相情感障碍管理的建议 (1)。双相情感障碍患者抑郁发作的急性期药物治疗,以下称为双相抑郁症的治疗,尤其具有挑战性。锂作为双相抑郁症治疗的证据有限且相互矛盾(2),因此在即将发布的指南中将该药物用于治疗双相抑郁症的定位特别令人感兴趣。
更新日期:2021-07-06
down
wechat
bug